At Fujifilm, we are committed to doing our part, at every opportunity, to deliver value through imaging innovation. ASPIRE Cristalle with Digital Breast Tomosynthesis (DBT) is built smarter because it is built with insight into image quality, operational excellence, and a better patient experience.
The intelligent design of ASPIRE Cristalle’s patented Comfort Paddle provides noticeably less pain and anxiety for the patient. With its unique flexible, slotted 4-way tilting paddle design, it provides more even compression, that combined with the Intelligent Automatic Exposure Control (iAEC) image processing, make it possible to provide more optimized images at low dose for every breast type, including implants.
Our advanced technology simplifies and speeds workflow so technologists can spend more time focused on patient interactions.
The unique Hexagonal Close Pattern (HCP) detector pixel design on ASPIRE Cristalle outperforms traditional pixel arrays to help enable superior diagnostic accuracy for radiologists.
When compared to square pixels, HCP delivers:
It’s critical to think about the bigger picture when introducing DBT to your facility to keep your facility running as efficiently as possible. Our Synapse® Enterprise Imaging portfolio, including Synapse 5 PACS and Synapse VNA, enables secure, easy-to-manage storage and access to the complete patient imaging record throughout the healthcare enterprise, regardless of the technology-generating source, format type, or siloed storage system.
The unique Comfort Paddle allows pressure to be more evenly and gently distributed across the breast compared to conventional, flexible paddles.
Learn more about the Comfort Paddle and other accessories here.
Contrast-enhanced digital mammography (CEDM) uses a dual-energy technique performed after the IV administration of iodinated contrast agent to identify abnormalities on the basis of angiogenesis, as well as morphologic features and density.
The physiologic information provided by CEDM is similar to that provided by breast MRI, without the added time or expense of conventional breast MRI protocols. The combination of morphologic and physiologic information provided by CEDM has been shown to provide superior sensitivity and specificity in diagnosing breast cancer when compared with digital mammography alone .
For many, the word mammogram is associated with anxiety and fear of a painful exam. Pain associated with mammography screenings results from compression of the breast, which is required to obtain high-quality mammograms at low radiation doses.
Comfort Comp leverages the phenomenon of hysteresis in which soft tissues, such as breast tissue, maintain their position for a period of time before returning to their neutral position. Mammography using Comfort Comp requires that normal breast compression be applied initially to ensure proper breast positioning and to take full advantage of the hysteresis principle. Comfort Comp triggers an automatic reduction in the amount of compression force after normal breast compression is completed and prior to exposure. Once completed, automatic decompression is activated, shortening the time that the breast is under maximum pressure with minimal changes to breast thickness or image quality.
Read the full white paper on Comfort Comp to learn how the feature is designed to augment patient comfort through decreased compression without compromising image quality or workflow.
View the Comfort Comp White Paper
Radiologists using ASPIRE Cristalle with DBT will realize valuable, enhanced clinical efficacy compared to using full field digital mammography (FFDM) alone.
Fujifilm’s proprietary technology makes it possible to lower dose while offering optimized contrast, even in dense breasts and implants.
Contact us and we can help you find the right product or service that will suit the needs of your patients and organization.
ASPIRE Cristalle, Fujifilm’s third-generation full-field digital mammography (FFDM) system, now delivers optimum image quality at a very low patient dose. A new white paper, Technology Advances in Mammography: Dose Reduction and Image Quality, highlights the recent advances in FFDM technology employed in the ASPIRE Cristalle system.
Download the white paper to learn how:
Fujifilm is committed to supporting technologists with continuing education offerings. Select from multiple webinar options to view and acquire CE credits.
This webinar will provide the audience with a unique perspective, that of a Medical Physicist, when evaluating and considering mammography systems from four different vendors. Discussion topics include elements to consider for a reliable mammography system, understanding the technology and system testing differences between each vendor, and the importance of an efficient QC testing process upon installation.
In this Expert Forum, Dr. Matthew Covington shares his understanding of the benefits and limitations of contrast-enhanced mammography, as compared to contrast-enhanced breast MRI, and how this imaging technique can be incorporated into clinical practice.
Dr. Laurie Fajardo will share her understanding of the benefits of synthetic 2D images with digital breast tomosynthesis (DBT) for diagnosing breast cancer along with considerations for implementing Synthetic 2D breast imaging protocols into your practice.
Fujifilm works with the following partners to provide additional features for ASPIRE Cristalle, ASPIRE HD Plus and ASPIRE HD.
iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers.
Volpara Solutions builds innovative, quantitative breast imaging solutions tools built on the Volpara algorithm which enables the generation of volumetric measurements of density, patient specific dose, breast compression and other factors that provide actionable intelligence designed to help maintain accuracy and consistent quality in breast screening.
To date, more than 2 million women have had their volumetric breast density analyzed using VolparaDensity. Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is used by radiologists to objectively assess density from both digital mammography and tomosynthesis images and help evaluate who might benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool which automatically generates an objective, automatic measurement of volumetric breast density and a FDA cleared BI-RADS breast density category.
VolparaAnalytics assists in quality assurance by monitoring critical elements of the breast imaging process and generating key metrics to help understand the performance of technologists, readers, and mammography and tomosynthesis machines.
VolparaDose improves the accuracy of mammography dose reporting by using a standard mean glandular dose (MGD) algorithm along with patient-specific volumetric breast density to give a better estimate of the dose absorbed by the specific breast.
